Abstracts

Vitaly A. Fishbein MD, FACG

1. Fishbein VA, Norton JA, Benya RV, Pisegna JR, Metz DC, Jensen RT. Prospective study of the best method to assess and predict cure in patients with Zollinger-Ellison syndrome (ZES) after tumor resection. Gastroenterology 1992; 102: A265.
2. Metz DC, Norton JA, Pisegna JR, Fishbein VA, Benya RV,Jensen RT. Do patients with Zollinger-Ellison syndrome (ZES) require gastric antisecretory therapy after curative gastrinoma resection? Gastroenterology 1992; 102: A125.
3. Pisegna JR, Metz DC, Norton JA, Fishbein VA, Benya RV, Jensen RT. Duodenal gastrinomas are more common, more malignant and less curable than g enerally believed. Gastroenterology 1992; 102: A286.
4. Metz DC, Pisegna JR, Ringham GL, Fishbein VA, Benya RV, Gardner JD, Jensen RT. Efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome (ZES). Gastroenterology 1992; 102: A125.
5. Benya RV, Metz DC, Norton JA, Fishbein VA, Pisegna JR,Jensen RT. The utility of fine needle aspiration cytology (FNAC) inthe evaluation of gastric and duodenal nodules in patients with Zollinger-Ellison syndrome.(ZES).1992 ACGE, Miami. October 1992.
6. Pisegna JR, Slimak GG, Metz DC, Fishbein VA, Jensen RT et al.: Human recombinant interferon in patients with metastatic gastrinoma: A prospective study. ASGE. Miami. October 1992.
7. V.A. Fishbeyn, J.A. Norton, D.L. Fraker, R.V. Benya, D.B. Strader, M. Orbuch, J.R. Pisegna, D.C. Metz, R.T Jensen. Prospective study of the best method to find duodenal gastrinomas in patients with Zollinger-Ellison syndrome. (ZES). AGA. Boston. May 1993.
8. V.A. Fishbeyn, D.H. Coy, N.Z. Jiang, R.T. Jensen. A Chimeric VIP-PACAP Analogue but not VIP Pseudopeptides function as VIP Receptor antagonists. AGA. Boston. May 1993
9. Strader DB, Orbuch M, Fishbein VA, Benya RV, Benjamin SB, Lubensky I, Jensen RT, Metz DC: Endoscopy, Manometry and Histopatology of the esophagus in Zollinger-Ellison Syndrome (ZES). AGA. Boston. May 1993
10. Benya RV, Metz DC, Fishbein VA, Strader DB, Orbuch M, Jensen RT : Gastrinoma can be the initial presentation for patients with Multiple Endocrine Neoplasia Type I (MEN-1). AGA. Boston. May 1993
11. H.C. Weber, D.J. Venzon, Fishbein VA, Strader DB, Orbuch M, F. Gibril, Jensen RT: Determinants of metastatic rate and survival in patients with Zollinger-Ellison Syndrome (ZES):Results of prospective long-term study. AGA. New Orleans. 1994.
12. H.C. Weber, D.J. Venzon, Fishbein VA, Strader DB, Orbuch M, F. Gibril, Jensen RT: Determinants of metastatic rate and survival in patients with Zollinger-Ellison Syndrome (ZES):Results of prospective long-term study. AGA. New Orleans. 1994.. The World Congresses of Gastroenterology. Los Angeles, CA. 1994